Literature DB >> 29078848

Partially Purified Gloriosa superba Peptides Inhibit Colon Cancer Cell Viability by Inducing Apoptosis Through p53 Upregulation.

Prapaphan Budchart1, Ariya Khamwut1, Chomdao Sinthuvanich1, Sunanta Ratanapo1, Yong Poovorawan2, Nattanan Panjaworayan T-Thienprasert3.   

Abstract

BACKGROUND: Colon cancer is a major health problem worldwide. Available treatments such as surgery, chemotherapy, radiation and anticancer drugs are limited due to stage of cancer, side effects and altered biodistribution. The use of peptides extracted from natural products has appeared as a potential therapy. Gloriosa superba is known to contain colchicine and other alkaloids with anticancer activity. However, these peptides contained within the extracts have not been studied. This study, therefore, focuses on an investigation of anti-colon cancer activity from a partially purified protein hydrolysate of G superba rhizome.
METHODS: Dried G superba rhizome was extracted using 0.5% sodium dodecyl sulfate and digested with pepsin. The protein hydrolysates with molecular weight lesser than 3kDa were collected and subjected for cell viability assay. Then, the partial purification of the protein hydrolysate was performed using reverse-phase high-performance liquid chromatography. Fractions containing anticancer peptides were investigated, and their effects on apoptosis and protein expression using apoptosis test and Western blot, respectively.
RESULTS: Partially purified peptides of G superba rhizome demonstrated anticolon activity in SW620 cells by inducing apoptosis through upregulation of p53 and downregulation of nuclear factor kappa B (NF-κB).
CONCLUSIONS: Consequently, G superba peptides showed high potential for further purification and development of anticolon therapeutics.
Copyright © 2017 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; Colon cancer; Gloriosa superba; Partially purified peptide; p53

Mesh:

Substances:

Year:  2017        PMID: 29078848     DOI: 10.1016/j.amjms.2017.06.005

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  7 in total

Review 1.  Anti-cancer activities of Schedule E1 drugs used in ayurvedic formulations.

Authors:  E N T Vikram; R Ilavarasan; R Kamaraj
Journal:  J Ayurveda Integr Med       Date:  2022-05-31

2.  Screening the elite chemotypes of Gloriosa superba L. in India for the production of anticancer colchicine: simultaneous microwave-assisted extraction and HPTLC studies.

Authors:  Devendra Kumar Pandey; Prabhjot Kaur; Vijay Kumar; R M Banik; Tabarak Malik; Abhijit Dey
Journal:  BMC Plant Biol       Date:  2021-02-05       Impact factor: 4.215

3.  Anticancer Secondary Metabolites: From Ethnopharmacology and Identification in Native Complexes to Biotechnological Studies in Species of Genus Astragalus L. and Gloriosa L.

Authors:  Iliana Ionkova; Aleksandar Shkondrov; Yancho Zarev; Ekaterina Kozuharova; Ilina Krasteva
Journal:  Curr Issues Mol Biol       Date:  2022-08-26       Impact factor: 2.976

4.  Verticillin A inhibits colon cancer cell migration and invasion by targeting c-Met.

Authors:  Qian-Qian Liu; Xue-Li Zeng; Yue-Lin Guan; Jing-Xin Lu; Kai Tu; Fei-Yan Liu
Journal:  J Zhejiang Univ Sci B       Date:  2020-10       Impact factor: 3.066

5.  Pro-apoptotic effects of Kangfuxin on human stomach cancer cells and its underlying mechanism.

Authors:  Xiuying Ma; Jia Sun; Weijian Ye; Yewei Huang; Congcong Sun; Youli Tao; Tao Wang; Weitao Cong; Funeng Geng
Journal:  Oncol Lett       Date:  2018-05-16       Impact factor: 2.967

6.  The mechanism of ATF3 repression of epithelial-mesenchymal transition and suppression of cell viability in cholangiocarcinoma via p53 signal pathway.

Authors:  Zhen You; Jingchang Xu; Bei Li; Hui Ye; Liping Chen; Yang Liu; Xianze Xiong
Journal:  J Cell Mol Med       Date:  2019-01-16       Impact factor: 5.310

Review 7.  Medicinal Plants in the Prevention and Treatment of Colon Cancer.

Authors:  Paola Aiello; Maedeh Sharghi; Shabnam Malekpour Mansourkhani; Azam Pourabbasi Ardekan; Leila Jouybari; Nahid Daraei; Khadijeh Peiro; Sima Mohamadian; Mahdiyeh Rezaei; Mahdi Heidari; Ilaria Peluso; Fereshteh Ghorat; Anupam Bishayee; Wesam Kooti
Journal:  Oxid Med Cell Longev       Date:  2019-12-04       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.